11-Keto-beta-boswellic acid
Based on 1 Customer Validation
11-Keto-beta-boswellic acid (11-Keto-β-boswellic acid) is a pentacyclic triterpenic acid of the oleogum resin from the bark of the Boswellia serrate tree, popularly known as Indian Frankincense. 11-Keto-beta-boswellic acid has the anti-inflammatory activity is primarily due to inhibit 5-lipoxygenase (5-LOX) and subsequent leukotriene and nuclear factor-kappa B (NF-κB) activation and tumor necrosis factor alpha generation production.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 99.90%
- CAS No.: 17019-92-0
- Formule: C30H46O4
- Masse moléculaire:470.68
-
Stockage:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
-
HY-N0892
AKBANrf2 Activator -
HY-N0140
Ursolic acidAutophagy Inducer -
HY-N2513
β-Boswellic acidLipoxygenase Inhibitor -
HY-N2075
3-Acetyl-beta-boswellic acidNatural Product -
HY-14164A
Zileuton sodium5-lipoxygenase Inhibitor -
HY-14164
Zileuton5-Lipoxygenase Inhibitor -
HY-N3037
3-O-Acetyl-α-boswellic acidT cell Function Suppressor -
HY-A0060
Malotilate5-LOX Inhibitor -
HY-N0892R
AKBA (Standard)Nrf2 Activator -
HY-14166
MK-886FLAP Inhibitor -
HY-N2056R
11-Keto-beta-boswellic acid (Standard)Anti-inflammatory Agent -
HY-12341
Onvoloxastat12-LOX Inhibitor
Voir tous les produits spécifiques à Isoform Leukotriene Receptor
More
Activité biologique
Description
IC50 & Target
[1]|
NF-κB |
5-LOX |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A253 cell line | IC50 |
45.9 μM
Compound: 3, (beta-KBA)
|
Cytotoxicity against human A253 cells assessed as cell survival after 96 hrs by SRB assay
Cytotoxicity against human A253 cells assessed as cell survival after 96 hrs by SRB assay
|
[PMID: 25618017] |
| A2780 | IC50 |
37.9 μM
Compound: 3, (beta-KBA)
|
Cytotoxicity against human A2780 cells assessed as cell survival after 96 hrs by SRB assay
Cytotoxicity against human A2780 cells assessed as cell survival after 96 hrs by SRB assay
|
[PMID: 25618017] |
| A549 | IC50 |
3 μM
Compound: 2
|
Inhibition of microsomal PGES1 isolated from IL-1beta-stimulated human A549 cells preincubated for 15 mins followed by substrate addition measured after 1 min by RP-HPLC analysis
Inhibition of microsomal PGES1 isolated from IL-1beta-stimulated human A549 cells preincubated for 15 mins followed by substrate addition measured after 1 min by RP-HPLC analysis
|
[PMID: 24844534] |
| DLD-1 | IC50 |
57.7 μM
Compound: 3, (beta-KBA)
|
Cytotoxicity against human DLD1 cells assessed as cell survival after 96 hrs by SRB assay
Cytotoxicity against human DLD1 cells assessed as cell survival after 96 hrs by SRB assay
|
[PMID: 25618017] |
| HCT-8 | IC50 |
44.6 μM
Compound: 3, (beta-KBA)
|
Cytotoxicity against human HCT8 cells assessed as cell survival after 96 hrs by SRB assay
Cytotoxicity against human HCT8 cells assessed as cell survival after 96 hrs by SRB assay
|
[PMID: 25618017] |
| HeLa | IC50 |
50 μM
Compound: 2, KBA
|
Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
|
[PMID: 21334793] |
| HL-60 | IC50 |
32 μM
Compound: 2, KBA
|
Cytotoxicity against human HL60 cells after 48 hrs by MTT assay
Cytotoxicity against human HL60 cells after 48 hrs by MTT assay
|
[PMID: 21334793] |
| HT-29 | IC50 |
71.9 μM
Compound: 3, (beta-KBA)
|
Cytotoxicity against human HT-29 cells assessed as cell survival after 96 hrs by SRB assay
Cytotoxicity against human HT-29 cells assessed as cell survival after 96 hrs by SRB assay
|
[PMID: 25618017] |
| Sf21 | IC50 |
>40 μM
Compound: 27
|
Inhibition of human recombinant COX2 expressed in baculovirus infected sf21 cells assessed as decrease in PGE2 formation using arachidonic acid as substrate preincubated for 10 mins followed by substrate addition measured after 45 mins by LC-MS analysis
Inhibition of human recombinant COX2 expressed in baculovirus infected sf21 cells assessed as decrease in PGE2 formation using arachidonic acid as substrate preincubated for 10 mins followed by substrate addition measured after 45 mins by LC-MS analysis
|
[PMID: 31774676] |
In Vitro
11-Keto-beta-boswellic acid inhibits DPP-4 activity with an IC50 of 1.65 µM[2].
11-Keto-beta-boswellic acid (10 min) inhibits 4-aminopyridine-stimulated glutamate release in rat hippocampal nerve terminals (IC50: 31 μM)[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
11-Keto-beta-boswellic acid (10 or 50 mg/kg, i.p.) protects rats against Kainic acid (HY-N2309) (15 mg/kg, i.p.)-induced excitotoxicity[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Streptozotocin (HY-13753)-induced diabetic rats[2]
-
Dosage:1-10 mg/kg
-
Administration:p.o., for 21 days
-
Result:Reduced blood glucose level.
Reduced the serum SGPT, SGOT, ALP, and serum creatinine level.
Decreased serum MDA level and increased serum SOD levels.
Chemical Information
-
CAS No. 17019-92-0
-
Appearance Solid
-
Masse moléculaire 470.68
-
Formule C30H46O4
-
Color White to off-white
-
SMILES
C[C@@]1([C@@]2(CC[C@]3(CC[C@H]([C@@H]([C@]3(C2=C4)[H])C)C)C)C)CC[C@@]5([H])[C@](C(O)=O)(C)[C@H](O)CC[C@]5(C)[C@@]1([H])C4=O
-
Synonyms
11-Keto-β-boswellic acid
-
Structure Classification
-
Initial Source
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Solvant et solubilité
In Vitro:
DMSO : 50 mg/mL (106.23 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (5.31 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.5 mg/mL (5.31 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocole
-
Cotton Pellet Granuloma
Cotton pellet granuloma is a classical in vivo chronic inflammation model used to evaluate the anti-inflammatory potential of test substances by measuring their ability to inhibit granuloma tissue formation around an implanted foreign body (cotton pellet) in rodents. The method is based on the biological response to a sterile implanted material, which induces proliferative phase inflammation characterized by fibroblast proliferation and collagen-rich granuloma formation, and the final readout reflects the extent of chronic inflammatory tissue growth surrounding the pellet. In multiple preclinical pharmacological evaluations, inhibition of cotton pellet-induced granuloma formation has been used as an indicator of anti-inflammatory activity in both synthetic and natural product screening contexts.
-
Carrageenan-Induced Paw Edema
Carrageenan-induced paw edema is an acute inflammation model in which intraplantar injection of carrageenan induces localized inflammatory swelling characterized by vascular permeability, leukocyte infiltration, and production of inflammatory mediators such as prostaglandins and cytokines, making it widely used to evaluate anti-inflammatory agents in vivo. The resulting paw volume or thickness increase is quantified over time as a direct readout of inflammatory intensity and drug efficacy, typically reflecting cyclooxygenase-mediated prostaglandin-driven edema formation and immune cell recruitment in peripheral tissue[20].
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
Pureté et documentation
-
Fiche technique (280 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instruction de manipulation (2659 KB)
Références
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.1246 mL | 10.6229 mL | 21.2459 mL | 53.1146 mL |
| 5 mM | 0.4249 mL | 2.1246 mL | 4.2492 mL | 10.6229 mL | |
| 10 mM | 0.2125 mL | 1.0623 mL | 2.1246 mL | 5.3115 mL | |
| 15 mM | 0.1416 mL | 0.7082 mL | 1.4164 mL | 3.5410 mL | |
| 20 mM | 0.1062 mL | 0.5311 mL | 1.0623 mL | 2.6557 mL | |
| 25 mM | 0.0850 mL | 0.4249 mL | 0.8498 mL | 2.1246 mL | |
| 30 mM | 0.0708 mL | 0.3541 mL | 0.7082 mL | 1.7705 mL | |
| 40 mM | 0.0531 mL | 0.2656 mL | 0.5311 mL | 1.3279 mL | |
| 50 mM | 0.0425 mL | 0.2125 mL | 0.4249 mL | 1.0623 mL | |
| 60 mM | 0.0354 mL | 0.1770 mL | 0.3541 mL | 0.8852 mL | |
| 80 mM | 0.0266 mL | 0.1328 mL | 0.2656 mL | 0.6639 mL | |
| 100 mM | 0.0212 mL | 0.1062 mL | 0.2125 mL | 0.5311 mL |
11-Keto-beta-boswellic acid Related Classifications
HY-N2056 Related Classifications
Powered by Bioz